Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including astrocytes; strongest in proximal tubule cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 53 | 0.74 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 15306
Sealed predictions
- TPCN1 in astrocytes, braak+0.50 (p 0.166) → -0.16 (p 0.680)receipt 15313
- TPCN1 in dopamine neurons, braak-0.62 (p 0.074) → -0.07 (p 0.852)receipt 15314
Swarm cases
receipt 15314: TPCN1 in dopamine neurons, braak
- power
- full sample -0.31 (p 0.218, n 18), 95% CI -0.68 to +0.19. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.35 (p 0.156, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.54 (p 0.019, n 18). not the mix.
- skeptic
- leave-one-out range -0.45 to -0.23, sign flips 0; without severely affected donors -0.31 (p 0.218, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.76 (p 2.7e-4, n 18) vs -0.31 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TPCN1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up TPCN1 · oligodendrocytes · braak: substantia nigra, an independent cohort (already registered)
receipt 15313: TPCN1 in astrocytes, braak
- power
- full sample +0.15 (p 0.549, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.21 (p 0.393, n 18). does not hold up.
- composition
- astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.36 (p 0.140, n 18). could be the mix.
- skeptic
- leave-one-out range +0.03 to +0.25, sign flips 0; without severely affected donors +0.15 (p 0.549, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.76 (p 2.7e-4, n 18) vs +0.15 in astrocytes. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TPCN1 in astrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up TPCN1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.25 p 0.374 (needs p < 1.5e-4)
Receipts
loading the receipts